The claimed invention relates to compositions that may be in a form of a liquid, solid, gel, cream or gel capsule comprising an analgesic, and methods for administering these compositions for treatment of patients suffering from various forms of pain.

Disclosed is a composition having an effect of alleviating bromhidrosis which contains dipotassium glycyrrhizinate, benzalkonium chloride, DL-camphor, a Houttuynia cordata extract and the like in order to eliminate side effects associated with triclosan. Further, disclosed is a composition having an effect of alleviating symptoms of bromhidrosis containing 11.5 parts by weight of purified water, 0.5 parts by weight of salicylic acid, 0.2 parts by weight of a fragrance, 7.5 parts by weight of butylene glycol, 0.055 parts by weight of allantoin, 0.255 parts by weight of dipotassium glycyrrhizinate, 0.03 parts by weight of benzalkonium chloride, 0.055 parts by weight of DL-camphor, 0.505 parts by weight of lavender oil and 0.505 parts by weight of a Houttuynia cordata extract, with reference to 80 parts by weight of ethanol.

Disclosed is a composition having an effect of alleviating bromhidrosis which contains dipotassium glycyrrhizinate, benzalkonium chloride, DL-camphor, a Houttuynia cordata extract and the like in order to eliminate side effects associated with triclosan. Further, disclosed is a composition having an effect of alleviating symptoms of bromhidrosis containing 11.5 parts by weight of purified water, 0.5 parts by weight of salicylic acid, 0.2 parts by weight of a fragrance, 7.5 parts by weight of butylene glycol, 0.055 parts by weight of allantoin, 0.255 parts by weight of dipotassium glycyrrhizinate, 0.03 parts by weight of benzalkonium chloride, 0.055 parts by weight of DL-camphor, 0.505 parts by weight of lavender oil and 0.505 parts by weight of a Houttuynia cordata extract, with reference to 80 parts by weight of ethanol.

Disclosed is a composition having an effect of alleviating bromhidrosis which contains dipotassium glycyrrhizinate, benzalkonium chloride, DL-camphor, a Houttuynia cordata extract and the like in order to eliminate side effects associated with triclosan. Further, disclosed is a composition having an effect of alleviating symptoms of bromhidrosis containing 11.5 parts by weight of purified water, 0.5 parts by weight of salicylic acid, 0.2 parts by weight of a fragrance, 7.5 parts by weight of butylene glycol, 0.055 parts by weight of allantoin, 0.255 parts by weight of dipotassium glycyrrhizinate, 0.03 parts by weight of benzalkonium chloride, 0.055 parts by weight of DL-camphor, 0.505 parts by weight of lavender oil and 0.505 parts by weight of a Houttuynia cordata extract, with reference to 80 parts by weight of ethanol.

The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.

The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.

The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.

Provided is a method for treating conditions and/or symptoms associated therewith selected from the group consisting of androgen deficiency, male infertility, male urogenital or reproductive system infections and/or disorders and combinations thereof, comprising administering to a subject in need a therapeutically effective amount of a composition comprising at least one cannabinoid in a specific amount, at least one terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene carrier, and optionally at least one herbal extract, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and a weight/weight ratio of a total amount of terpenes to a total amount of cannabinoids is from about 0.1:1 to about 1:1, or; wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and a weight/weight ratio of a total amount of terpenes to a total amount cannabinoids is about 0.05:1 to about 1:1.

Provided is a method for treating conditions and/or symptoms associated therewith selected from the group consisting of androgen deficiency, male infertility, male urogenital or reproductive system infections and/or disorders and combinations thereof, comprising administering to a subject in need a therapeutically effective amount of a composition comprising at least one cannabinoid in a specific amount, at least one terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene carrier, and optionally at least one herbal extract, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and a weight/weight ratio of a total amount of terpenes to a total amount of cannabinoids is from about 0.1:1 to about 1:1, or; wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and a weight/weight ratio of a total amount of terpenes to a total amount cannabinoids is about 0.05:1 to about 1:1.

This disclosure pertains to devices and methods for administering one or more active ingredients, e.g., cannabinoids, terpenes, etc. In particular, the devices and methods disclosed herein administer one or more cannabinoids in a mist for transmucosal and transdermal absorption. In one embodiment, the device contains compositions comprising purified active ingredients (e.g., cannabinoids, terpenes, etc.) and/or unique combinations thereof for delivery via a mist for transmucosal and transdermal adsorption. In one embodiment, the device contains two separate compositions in separate chambers, wherein each composition comprises one or more of the active ingredients. In one embodiment, a composition in one chamber comprises a purified cannabinoid and the composition in the other chamber comprises a purified terpene. In an embodiment, the device operates without heating the active ingredients.